Oral hormone therapy with 17??-estradiol and 17??-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects
- 1 November 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Menopause
- Vol. 12 (6), 741-748
- https://doi.org/10.1097/01.gme.0000184425.73567.12
Abstract
A 2-year multicenter, double-blind, randomized, placebo-controlled study examined the efficacy and safety of different doses of 17beta-estradiol (E(2)) alone and continuous-combined oral formulations of E(2) and norethindrone acetate (NETA) versus placebo in the prevention of bone loss in newly menopausal women. Patients were randomized to one of seven groups: placebo, E(2) 0.25 mg, E2 0.5 mg, E(2) 1 mg, E(2) 1 mg/NETA 0.25 mg, E(2) 1 mg/NETA 0.5 mg, or E(2) 2 mg/NETA 1 mg. Treatment was a once-daily tablet taken for 26 months. The primary efficacy endpoint was the change in bone mineral density (BMD) at the lumbar spine, measured by dual-energy x-ray absorptiometry, at screening and at 13, 19, and 26 months. BMD changes at the femoral neck and trochanter were also assessed. Biochemical markers of bone metabolism were measured at baseline, and at 3, 6, 13, 19, and 26 months. Histological diagnoses of endometrial samples were tabulated for each treatment group. A total of 327 women were randomized and 189 women completed the 2-year trial. BMD at the lumbar spine decreased 2.3% in the placebo group. The lowest dose of unopposed E(2) prevented bone loss at the spine and hip. Significant increases in spine BMD compared with placebo occurred in all groups of treatment with E(2) and were more pronounced in the combination groups. Compared with placebo, women receiving active treatment experienced greater reductions in bone resorption markers. The effects were evident by 6 months and generally remained stable thereafter. Adverse events, primarily associated with the endometrium, were the most common reasons for discontinuation. There is a dose-dependent effect of E(2) on BMD. The addition of NETA seems to enhance the response in BMD observed with E(2). Low doses of E(2) (1 mg and lower) can be considered for the prevention of osteoporosis, while titrating the hormone dose to individual patient's needs.Keywords
This publication has 36 references indexed in Scilit:
- Bone Mass Response to Discontinuation of Long-term Hormone Replacement TherapyResults From the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up StudyArchives of Internal Medicine, 2002
- Preventing and Treating OsteoporosisAnnals of the New York Academy of Sciences, 2001
- A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging MenJournal of Bone and Mineral Research, 1998
- Low-dosage micronized 17ß-estradiol prevents bone loss inpostmenopausal womenAmerican Journal of Obstetrics and Gynecology, 1992
- Hormone Replacement Therapy and the Risk for First Hip FractureAnnals of Internal Medicine, 1990
- Hip Fracture and the Use of Estrogens in Postmenopausal WomenNew England Journal of Medicine, 1987
- Long-Term Estrogen Replacement Therapy Prevents Bone Loss and FracturesAnnals of Internal Medicine, 1985
- Relative Contributions of Aging and Estrogen Deficiency to Postmenopausal Bone LossNew England Journal of Medicine, 1984
- Menopausal Estrogen Therapy and Hip FracturesAnnals of Internal Medicine, 1981
- Decreased Risk of Fractures of the Hip and Lower Forearm with Postmenopausal Use of EstrogenNew England Journal of Medicine, 1980